These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice. He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508 [TBL] [Abstract][Full Text] [Related]
4. Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. Kislin KL; Marron MT; Li G; Graner MW; Katsanis E FASEB J; 2007 Jul; 21(9):2173-84. PubMed ID: 17327358 [TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Zeng Y; Graner MW; Feng H; Li G; Katsanis E Int J Cancer; 2004 Jun; 110(2):251-9. PubMed ID: 15069690 [TBL] [Abstract][Full Text] [Related]
7. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells. Feng H; Zeng Y; Graner MW; Katsanis E Blood; 2002 Dec; 100(12):4108-15. PubMed ID: 12393401 [TBL] [Abstract][Full Text] [Related]
8. [Construction of genetically modified dendritic cell vaccine expressing bcr/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro]. Wang WW; Huang RW; Hu Y; Li XD; Wang DN; He Y; Liu JJ Ai Zheng; 2009 Jun; 28(6):602-6. PubMed ID: 19635197 [TBL] [Abstract][Full Text] [Related]
9. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia. Janikashvili N; LaCasse CJ; Larmonier C; Trad M; Herrell A; Bustamante S; Bonnotte B; Har-Noy M; Larmonier N; Katsanis E Blood; 2011 Feb; 117(5):1555-64. PubMed ID: 21123824 [TBL] [Abstract][Full Text] [Related]
16. Exosomes from Dendritic Cells Loaded with Chaperone-Rich Cell Lysates Elicit a Potent T Cell Immune Response Against Intracranial Glioma in Mice. Bu N; Wu H; Zhang G; Zhan S; Zhang R; Sun H; Du Y; Yao L; Wang H J Mol Neurosci; 2015 Jul; 56(3):631-43. PubMed ID: 25680514 [TBL] [Abstract][Full Text] [Related]
17. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. Casnici C; Volpe G; Lattuada D; Crotta K; Kuka M; Panuzzo C; Mastrotto C; Tonon G; Fazio VM; Saglio G; Marelli O Cancer Lett; 2009 Apr; 276(1):61-7. PubMed ID: 19062160 [TBL] [Abstract][Full Text] [Related]
18. Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes. Makita M; Azuma T; Hamaguchi H; Niiya H; Kojima K; Fujita S; Tanimoto M; Harada M; Yasukawa M Leukemia; 2002 Dec; 16(12):2400-7. PubMed ID: 12454745 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]